C
C. Barbara
Researcher at University of Pisa
Publications - 33
Citations - 2112
C. Barbara is an academic researcher from University of Pisa. The author has contributed to research in topics: FOLFOXIRI & FOLFIRI. The author has an hindex of 16, co-authored 33 publications receiving 1779 citations.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
Alfredo Falcone,Sergio Ricci,Isa Brunetti,Elisabetta Pfanner,Giacomo Allegrini,C. Barbara,Lucio Crinò,Giovanni Benedetti,W. Evangelista,Laura Fanchini,Enrico Cortesi,V. Picone,Stefano Vitello,Silvana Chiara,Cristina Granetto,Gianfranco Porcile,Luisa Fioretto,Cinzia Orlandini,Michele Andreuccetti,Gianluca Masi +19 more
TL;DR: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
Journal ArticleDOI
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Chiara Cremolini,Daniele Rossini,Emanuela Dell'Aquila,Sara Lonardi,Elena Conca,Marzia Del Re,Adele Busico,Filippo Pietrantonio,Romano Danesi,Giuseppe Aprile,Emiliano Tamburini,Carlo Barone,Gianluca Masi,Francesco Pantano,Francesca Pucci,Domenico Corsi,Nicoletta Pella,Francesca Bergamo,Eleonora Rofi,C. Barbara,Alfredo Falcone,Daniele Santini +21 more
TL;DR: This is the first prospective demonstration that a rechallenge strategy with cetuximab and irinotecan may be active in patients with RAS and BRAF wild-type mCRC with acquired resistance to first-line irinOTecan- and cetUXimab-based therapy.
Journal ArticleDOI
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
Gianluca Masi,Lisa Salvatore,Luca Boni,Fotios Loupakis,Chiara Cremolini,Lorenzo Fornaro,Marta Schirripa,Samanta Cupini,C. Barbara,V. Safina,Cristina Granetto,E. Fea,Lorenzo Antonuzzo,Corrado Boni,Giacomo Allegrini,Silvana Chiara,Domenico Amoroso,Andrea Bonetti,Alfredo Falcone +18 more
TL;DR: This study demonstrates that the continuation or the reintroduction of bevacizumab with second-line chemotherapy beyond first progression improves the outcome and supports the use of this strategy in the treatment of mCRC.
Journal ArticleDOI
An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human Plasma
Stefano Fogli,Romano Danesi,Federico Innocenti,A. Di Paolo,Guido Bocci,C. Barbara,M. Del Tacca +6 more
TL;DR: Overall results indicate that it is feasible to analyze all the anthracyclines used in clinical practice and their major metabolites with a single optimized method, thereby simplifying their monitoring in chemotherapeutic regimens of cancer patients.
Journal ArticleDOI
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Guido Bocci,C. Barbara,Francesca Vannozzi,Antonello Di Paolo,Alessandro Melosi,G. Barsanti,Giacomo Allegrini,Alfredo Falcone,Mario Del Tacca,Romano Danesi +9 more
TL;DR: To avoid severe 5‐FU toxicities in patients with greatly impaired5‐FU and 5‐FDHU pharmacokinetic parameters of the test dose related to the most common drug toxicities that affect patients after the first cycle of 5-FU chemotherapy, a reduced test dose is administered.